Caitong International Asset Management Co. Ltd Acquires Shares of 509 AstraZeneca PLC $AZN

Caitong International Asset Management Co. Ltd purchased a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the 1st quarter, Holdings Channel.com reports. The firm purchased 509 shares of the company’s stock, valued at approximately $37,000.

Several other large investors have also modified their holdings of AZN. Banque Transatlantique SA purchased a new stake in shares of AstraZeneca during the fourth quarter worth approximately $26,000. Confluence Investment Management LLC acquired a new position in AstraZeneca during the first quarter worth $27,000. Larson Financial Group LLC grew its holdings in AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after acquiring an additional 289 shares during the period. Mascagni Wealth Management Inc. acquired a new position in AstraZeneca during the fourth quarter worth $29,000. Finally, FNY Investment Advisers LLC acquired a new position in AstraZeneca during the first quarter worth $29,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Separately, Berenberg Bank set a $97.00 price objective on AstraZeneca in a report on Wednesday, July 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Trading Up 0.9%

Shares of AZN stock opened at $79.17 on Monday. The business’s fifty day moving average price is $72.32 and its 200 day moving average price is $71.91. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The firm has a market capitalization of $245.53 billion, a PE ratio of 29.76, a P/E/G ratio of 1.46 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%. The business had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.08 billion. During the same quarter last year, the business posted $1.24 earnings per share. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Monday, September 8th. Stockholders of record on Friday, August 8th will be given a $0.505 dividend. The ex-dividend date is Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s dividend payout ratio (DPR) is currently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.